Opportunities to Apply the 3Rs in Safety Assessment Programs-Reference-Cited by-同舟云学术

Opportunities to Apply the 3Rs in Safety Assessment Programs

Published:2016-12 Issue:2 Volume:57 Page:234-245
ISSN:1084-2020
Container-title:ILAR Journal
language:en
Short-container-title:ILAR J

Author:

Sewell Fiona,Edwards Joanna,Prior Helen,Robinson Sally

Publisher

Oxford University Press (OUP)

Subject

General Biochemistry, Genetics and Molecular Biology,Animal Science and Zoology,General Medicine

Reference104 articles.

1. 2010/63/EU . 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.

2. Safety pharmacology investigations in toxicology studies: an industry survey;Authier;J Pharmacol Toxicol Methods,2013

3. Safety evaluation to support first-in-man investigations II: Toxicology studies

4. Safety evaluation of biological drugs: What are toxicology studies in primates telling us?

5. Exploratory drug safety: A discovery strategy to reduce attrition in development

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Liver-Chip data into pharmaceutical decision-making processes;Expert Opinion on Drug Discovery;2023-09-12

2. CSL-Tox: an open-source analytical framework for the comparison of short-term and long-term toxicity end points and assessing the need of chronic studies in drug development;Scientific Reports;2023-09-08

3. Regulations and ethics concerning the use of non-human primates in research;Spontaneous Pathology of the Laboratory Non-Human Primate;2023

4. Scientific and Regulatory Policy Committee Best Practices: Recommended (“Best”) Practices for Informed (Non-blinded) Versus Masked (Blinded) Microscopic Evaluation in Animal Toxicity Studies;Toxicologic Pathology;2022-11-14

5. CSL-Tox: An open-source analytical framework for the comparison of short-term and long-term toxicity end points and exploring the opportunities for decreasing in-vivo studies conducted for drug development programs;2022-08-07